Compare Quest Diagnostics Inc (DGX) vs Msci Inc (MSCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Msci Inc — how do they compare? Quest Diagnostics Inc trades at $237.9 (market cap $26.21B), while Msci Inc trades at $560.9 (market cap $40.84B). The key difference: Msci Inc is the larger of the two by market cap, and Msci Inc pays the higher dividend (1.46%). Which is the better fit depends on your goals.
| DGX | MSCI | |
|---|---|---|
Market Cap | $26.21B | $40.84B |
Sector | Health | Financials |
52-Week High | $238.50 | $643.83 |
52-Week Low | $173.49 | $511.84 |
Enterprise Value | $31.97B | $47.00B |
Dividend Yield | 1.45% | 1.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
MSCI trades at $562.00, down 0.19% in the last 24 hours, with a bearish technical signal from moving averages but oversold RSI hints at potential rebound. The company reported Q2 2026 EPS of $4.94, slightly missing the $4.99 estimate, yet revenue growth remains robust, with 2025 revenue at $3.13 billion and net income margin of 40.73%. Recent acquisitions like First Street and partnerships with UBS aim to expand its private markets analytics platform, supporting long-term growth.
Outlook is positive with a consensus price target of $728.14, implying 30% upside, driven by strong recurring revenue and high client retention. Risks include elevated debt levels of $4.51 billion and competitive pressures in financial data services. Analysts maintain 73% buy ratings, citing undervaluation relative to growth prospects, but investors should monitor execution on integration of recent acquisitions and interest rate impacts on financing costs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →
